Evidenced based medicine and drugs approved for the treatment of osteoporosis. Role of calcium and vitamin D;La medicina basada en la evidencia y los fármacos aprobados para el tratamiento de la osteoporosis. Papel del calcio y la vitamina

Revista Clinica Espanola

Volumn 209, Issue 1, 2009, Pages

  Sosa Henriquez M ^a   Gomez De Tejada Romero M J ^b  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Calcium; Fracture; Osteoporosis; Treatment; Vitamin D

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM CARBONATE; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID; CALCIUM;

ALCOHOL CONSUMPTION; BONE DENSITY; CIGARETTE SMOKING; CLINICAL PRACTICE; CLINICAL TRIAL; DIET; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EXERCISE; FRACTURE; HEALTH CARE PLANNING; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; PATIENT COMPLIANCE;

CALCIUM; EVIDENCE-BASED MEDICINE; HUMANS; OSTEOPOROSIS; PATIENT COMPLIANCE; VITAMIN D;

EID: 63849180347     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/S0014-2565(09)70355-8     Document Type: Review

References (82)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South Med J. 2001;94(6):569-73.
2. R.R. Recker, and M.J. Barger-Lux The elusive concept of bone quality Curr Osteoporos Rep 2 3 2004 97 100
3. C.S. Colon-Emeric, and K.G. Saag Osteoporotic fractures in older adults Best Pract Res Clin Rheumatol 20 4 2006 695 706
4. T.W. O'Neill, and D.K. Roy How many people develop fractures with what outcome? Best Pract Res Clin Rheumatol 19 6 2005 879 895
5. S.R. Cummings, and L.J. Melton Epidemiology and outcomes of osteoporotic fractures Lancet 359 9319 2002 1761 1767
6. Evidence-based medicine A new approach to teaching the practice of medicine JAMA 268 17 1992 2420 2425
7. D.L. Sackett, W.M. Rosenberg, J.A. Gray, R.B. Haynes, and W.S. Richardson Evidence based medicine: what it is and what it isn't BMJ 312 7023 1996 71 72
8. K. Dickersin, S.E. Straus, and L.A. Bero Evidence based medicine: increasing, not dictating, choice BMJ 334 Suppl 1 2007 S10
9. M.J. Gómez de Tejada Romero, and M. Sosa Henríquez ¿Qué queremos decir exactamente con "fracturas no vertebrales"? (O ¿por qué no llamar a las cosas por su nombre?) Rev Esp Enf Metabol Oseas 14 2005 39 40
10. G. Divittorio, K.L. Jackson, V.L. Chindalore, W. Welker, and J.B. Walker Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis Pharmacotherapy 26 1 2006 104 114
11. S.T. Harris, N.B. Watts, H.K. Genant, C.D. McKeever, T. Hangartner, and M. Keller Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 14 1999 1344 1352
12. C.H. Chesnut 3rd, S. Silverman, K. Andriano, H. Genant, A. Gimona, and S. Harris A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group Am J Med 109 4 2000 267 276
13. T. Kehoe Bone quality: a perspective from the Food and Drug Administration Curr Osteoporos Rep 4 2 2006 76 79
14. M.L. Bouxsein Bone quality: where do we go from here? Osteoporos Int 14 Suppl 5 2003 S118 S127
15. P.J. Meunier Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomized clinical trials Int J Clin Pract 53 2 1999 122 129
16. T. Storm, G. Thamsborg, T. Steiniche, H.K. Genant, and O.H. Sorensen Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis N Engl J Med 322 18 1990 1265 1271
17. D.M. Black, D.E. Thompson, D.C. Bauer, K. Ensrud, T. Musliner, and M.C. Hochberg Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 11 2000 4118 4124
18. S.R. Cummings, D.M. Black, D.E. Thompson, W.B. Applegate, E. Barrett- Connor, and T.A. Muslines Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial JAMA 280 24 1998 2077 2082
19. J. Reginster, H.W. Minne, O.H. Sorensen, M. Hooper, C. Roux, and M.L. Brandi Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 1 2000 83 91
20. M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, and C. Roux Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 5 2001 333 340
21. I.C. Chesnut, A. Skag, C. Chrstiansen, R. Recker, J.A. Stakkestad, and A. Hoiseth Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 8 2004 1241 1249
22. D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, and J.A. Cauley Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 18 2007 1809 1822
23. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, and H.K. Genant Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 7 1999 637 645
24. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, and J.Y. Reginster Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 19 2001 1434 1441
25. S.L. Greenspan, H.G. Bone, M.P. Ettinger, D.A. Hanley, R. Lindsay, and J.R. Zanchetta Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial Ann Int Med 146 5 2007 326 339
26. J.Y. Reginster, E. Seeman, M.C. De Vernejoul, S. Adami, J. Compston, and C. Phenekos Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 5 2005 2816 2822
27. P.J. Meunier, C. Roux, E. Seeman, S. Ortolani, J.E. Badurski, and T.D. Spector The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 5 2004 459 468
28. H.A. Bischoff-Ferrari, W.C. Willett, J.B. Wong, E. Giovannucci, T. Dietrich, and B. Dawson-Hughes Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials JAMA 293 18 2005 2257 2264
29. S. Boonen, P. Lips, R. Bouillon, H.A. Bischoff-Ferrari, D. Vanderschueren, and P. Haentjens Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials J Clin Endocrinol Metabol 92 4 2007 1415 1423
30. B.M. Tang, G.D. Eslick, C. Nowson, C. Smith, and A. Bensoussan Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis Lancet 370 9588 2007 657 666
31. C. Jackson, S. Gaugris, S.S. Sen, and D. Hosking The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a metaanalysis QJM 100 4 2007 185 192
32. H.A. Bischoff-Ferrari, B. Dawson-Hughes, W.C. Willett, H.B. Staehelin, M.G. Bazemore, and R.Y. Zee Effect of Vitamin D on falls: a meta-analysis JAMA 291 16 2004 1999 2006
33. E. Segal, A. Tamir, and S. Ish-Shalom Compliance of osteoporotic patients with different treatment regimens Isr Med Assoc J 5 12 2003 859 862
34. J.A. Kotzan, B.C. Martin, and W.E. Wade Persistence with estrogen therapy in a postmenopausal Medicaid population Pharmacotherapy 19 3 1999 363 369
35. D.H. Solomon, J. Avorn, J.N. Katz, J.S. Finkelstein, M. Arnold, and J.M. Polinski Compliance with osteoporosis medications Arch Int Med 165 20 2005 2414 2419
36. B. Ettinger, A. Pressman, and C. Bradley Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen Menopause 5 3 1998 152 156
37. D.L. Faulkner, C. Young, D. Hutchins, and J.S. McCollam Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database Menopause 5 4 1998 226 229
38. A. Cano Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre Maturitas 20 2-3 1994 91 99
39. M. Sosa, M.C. Navarro Rodríguez, M.C. Segarra Sánchez, C. Cabrera Domínguez, J.M. Limiñana Cañal, and D. Hernández Hernández Cumplimiento del tratamiento hormonal sustitutivo en la menopausia en una población canaria. Seguimiento durante 3 años Rev Esp Enf Metabol Oseas 3 1994 150 154
40. A.N. Tosteson, M.R. Grove, C.S. Hammond, M.M. Moncur, G.T. Ray, and G.M. Heber Early discontinuation of treatment for osteoporosis Am J Med 115 3 2003 209 216
41. C. Turbi, G. Herrero-Beaumont, J.C. Acebes, A. Torrijos, J. Grana, and R. Miguelez Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study Clin Ther 26 2 2004 245 256
42. M. Rossini, G. Bianchi, O. Di Munno, S. Giannini, S. Minisola, and L. Sinigaglia Determinants of adherence to osteoporosis treatment in clinical practice Osteoporos Int 17 6 2006 914 921
43. A. Papaioannou, C.C. Kennedy, L. Dolovich, E. Lau, and J.D. Adachi Patient adherence to osteoporosis medications: problems, consequences and management strategies Drugs Aging 24 1 2007 37 55
44. J.S. McCombs, P. Thiebaud, C. McLaughlin-Miley, and J. Shi Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 3 2004 271 287
45. E.G. Pasion, S.K. Sivananthan, A.W. Kung, S.H. Chen, Y.J. Chen, and R. Mirasol Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women J Bone Miner Metabol 25 2 2007 105 113
46. J.D. Ringe, G.E. Christodoulakos, D. Mellstrom, H. Petto, T. Nickelsen, and F. Marin Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women Curr Med Res Opin 23 11 2007 2677 2687
47. F. Lekkerkerker, J.A. Kanis, N. Alsayed, G. Bouvenot, N. Burlet, and D. Cahall Adherence to treatment of osteoporosis: a need for study Osteoporos Int 18 10 2007 1311 1317
48. E.S. Siris, S.T. Harris, C.J. Rosen, C.E. Barr, J.N. Arvesen, and T.A. Abbott Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 8 2006 1013 1022
49. J.J. Caro, K.J. Ishak, K.F. Huybrechts, G. Raggio, and C. Naujoks The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 12 2004 1003 1008
50. K.F. Huybrechts, K.J. Ishak, and J.J. Caro Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 6 2006 922 928
51. J. Adachi, N. Lynch, H. Middelhoven, M. Hunjan, and W. Cowell The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review BMC Musculoskelet Disord 8 2007 97
52. C.H. van den Boogaard, N.S. Breekveldt-Postma, S.E. Borggreve, W.G. Goettsch, and R.M. Herings Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study Curr Med Res Opin 22 9 2006 1757 1764
53. L. Fraenkel, B. Gulanski, and D. Wittink Patient treatment preferences for osteoporosis Arthritis Rheum 55 5 2006 729 735
54. R. Emkey, W. Koltun, K. Beusterien, L. Seidman, A. Kivitz, and V. Devas Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, crossover trial: the Boniva Alendronate Trial in Osteoporosis (BALTO) Curr Med Res Opin 21 12 2005 1895 1903
55. J. Payer, Z. Killinger, I. Sulkova, and P. Celec Preferences of patients receiving bisphosphonates - how to influence the therapeutic adherence Biomed Pharmacother 62 2 2008 122 124
56. D.T. Gold, W. Safi, and H. Trinh Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate Curr Med Res Opin 22 12 2006 2383 2391
57. R. Keen, E. Jodar, G. Iolascon, H.P. Kruse, A. Varbanov, and B. Mann European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency Curr Med Res Opin 22 12 2006 2375 2381
58. D. Kendler, A.W. Kung, H. Fuleihan Gel, J.G. González González, K.A. Gaines, and N. Verbruggen Patients with osteoporosis prefer once weekly to once daily dosing with alendronate Maturitas 48 3 2004 243 251
59. R.B. Haynes, X. Yao, A. Degani, S. Kripalani, A. Garg, and H.P. McDonald Interventions to enhance medication adherence Cochrane database of systematic reviews (Online) 4 2005 CD000011
60. R.B. Haynes, K.A. McKibbon, and R. Kanani Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications Lancet 348 9024 1996 383 386
61. K. Sakhaee, T. Bhuket, B. Adams-Huet, and D.S. Rao Meta-analysis of calcium bioavailability: a comparison of calcium citrate with calcium carbonate Am J Ther 6 6 1999 313 321
62. Is calcium citrate better than other calcium supplements? Johns Hopkins Med Lett Health After 50. 2000;12(4):8.
63. R.P. Heaney, M.S. Dowell, and M.J. Barger-Lux Absorption of calcium as the carbonate and citrate salts, with some observations on method Osteoporos Int 9 1 1999 19 23
64. L. Patrick Comparative absorption of calcium sources and calcium citrate malate for the prevention of osteoporosis Altern Med Rev 4 2 1999 74 85
65. P.O. Schwille, A. Schmiedl, U. Herrmann, R. Schwille, E. Fink, and M. Manoharan Acute oral calcium-sodium citrate load in healthy males. Effects on acid-base and mineral metabolism, oxalate and other risk factors of stone formation in urine Methods Find Exp Clin Pharmacol 19 6 1997 417 427
66. R.R. Recker Calcium absorption and achlorhydria N Engl J Med 33 2 1985 70 73
67. P. Aguado, M.T. del Campo, M.V. Garces, M.L. González-Casaus, M. Bernad, and J. Gijón-Banos Low vitamin D levels in outpatient postmenopausal women from a rheumatology clinic in Madrid, Spain: their relationship with bone mineral density Osteoporos Int 11 9 2000 739 744
68. J.M. Quesada, I. Jans, P. Benito, J.A. Jiménez, and R. Bouillon Vitamin D status of elderly people in Spain Age Ageing 18 6 1989 392 397
69. S. Gaugris, R.P. Heaney, S. Boonen, H. Kurth, J.D. Bentkover, and S.S. Sen Vitamin D inadequacy among post-menopausal women: a systematic review QJM 98 9 2005 667 676
70. O. Bruyere, O. Malaise, A. Neuprez, J. Collette, and J.Y. Reginster Prevalence of vitamin D inadequacy in European postmenopausal women Curr Med Res Opin 23 8 2007 1939 1944
71. A. Neuprez, O. Bruyere, J. Collette, and J.Y. Reginster Vitamin D inadequacy in Belgian postmenopausal osteoporotic women BMC Public Health 7 147 2007 64
72. P. Lips, D. Hosking, K. Lippuner, J.M. Norquist, L. Wehren, and G. Maalouf The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation J Int Med 260 3 2006 245 254
73. R. Rizzoli, J.A. Eisman, J. Norquist, O. Ljunggren, G. Krishnarajah, and S.K. Lim Risk factors for vitamin D inadequacy among women with osteoporosis: an international epidemiological study Int J Clin Pract 60 8 2006 1013 1019
74. M.F. Holick High prevalence of vitamin D inadequacy and implications for health Mayo Clin Proc 81 3 2006 353 373
75. T. Dixon, P. Mitchell, T. Beringer, S. Gallacher, C. Moniz, and S. Patel An overview of the prevalence of 25-hydroxy-vitamin D inadequacy amongst elderly patients with or without fragility fracture in the United Kingdom Curr Med Res Opin 22 2 2006 405 415
76. P. Ryan, and T. Dixon Prevalence of vitamin D inadequacy in patients attending a metabolic bone clinic in Medway Curr Med Res Opin 22 1 2006 211 216
77. T. Beringer, G. Heyburn, M. Finch, C. McNally, M. McQuilken, and M. Duncan Prevalence of vitamin D inadequacy in Belfast following fragility fracture Curr Med Res Opin 22 1 2006 101 105
78. C. Moniz, T. Dew, and T. Dixon Prevalence of vitamin D inadequacy in osteoporotic hip fracture patients in London Curr Med Res Opin 21 12 2005 1891 1894
79. S.J. Gallacher, C. McQuillian, M. Harkness, F. Finlay, A.P. Gallagher, and T. Dixon Prevalence of vitamin D inadequacy in Scottish adults with non-vertebral fragility fractures Curr Med Res Opin 21 9 2005 1355 1361
80. M.F. Holick, E.S. Siris, N. Binkley, M.K. Beard, A. Khan, and J.T. Katzer Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy J Clin Endocrinol Metab 90 6 2005 3215 3224
81. P. Mezquita-Raya, M. Muñoz-Torres, J.D. Luna, V. Luna, F. López- Rodríguez, and E. Torres-Vela Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women J Bone Miner Res 16 8 2001 1408 1415
82. J. Sebastián-Pérez Martínez, and M.T. Gea-Velázquez de Castro Realidad de la prescripción y grado de cumplimiento de los suplementos de calcio + vitamina D en el tratamiento de la osteoporosis en la Atención Primaria de Andalucía. Estudio SOL-D8 SEMERGEN 34 2008 52 58